Dinamika kaum santri : menelusuri jejak dan pergolakan internal NU

xxiii, 236 p.; 20 cm

Dinamika Kaum Santri : Menelusuri Jejak &* Pergolakan Internal NU

xxii + 236 hal.: 21 C

Diurnal Variation of Blood Pressure and Arterial Stiffness in Chronic Kidney Disease

Hypertension and chronic kidney disease (CKD) are interrelated public health problems throughout the world. Hypertension accompanied by CKD is mostly difficult to control. Difficulty in controlling blood pressure (BP) is known from changes in the diurnal variation of BP over 24 hours in CKD patients with a pattern of non-dipping and reverse dipping at night and an increase in pulse pressure due to arterial stiffness that occurs in CKD, resulting in a high incidence of nocturnal hypertension and masked hypertension. Nocturnal hypertension in CKD has a significant prognostic risk of increased risk of cardiovascular disease and cause of death. Therefore, guidelines for the management of hypertension strongly recommend that patients with hypertension have blood pressure well controlled at all times, especially to improve hypertension control at night in CKD patients

Renal Amyloidosis: A Narrative Literature Review

Amyloidosis is a disorder in which soluble proteins aggregate and are deposited extracellularly in tissues as insoluble fibrils, causing progressive organ dysfunction. Amyloid fibril formation begins with misfolding of amyloidogenic precursor proteins. The fibrils have a characteristic appearance by electron microscopy and produce double refraction under polarized light when stained with Congo red dye. Classification of amyloidosis is based on the precursor proteins that form amyloid fibrils and the distribution of amyloid deposition both systemically and locally. The main form of systemic amyloidosis; AL amyloid, AA amyloidosis, ATTR amyloid. The kidney is the organ most frequently involved in systemic amyloidosis. Systemic amyloidosis may originate from anomalous proteins, such as immunoglobulin light chains or serum amyloid protein in chronic inflammation or may arise from hereditary disorders. The clinical manifestations of renal amyloidosis vary with the type of amyloid protein and the location and extent of amyloid deposition. Treatment of amyloidosis should be a two-part process; managing symptoms and reducing or stabilizing amyloid protein. Treatment of amyloidosis is focused on reducing the production of amyloidogenic proteins and inhibiting their aggregation

Papillary Renal Cell Carcinoma Type 1 Accompanied by Hemorrhagic Anemia: A Case Report

Background: Kidney cancer or renal cell carcinoma (RCC) accounts for 5% and 3% of all adult malignancies in men and women, respectively, thus representing the 7th most common cancer in men, and the 10th most common cancer in women. The incidence of kidney cancer in the last two decades has shown an increase, but in recent years the death rate due to kidney cancer has decreased because it is increasing. Case Presentation: A 27 year old male patient came with complaints of bloody urination. Patients also complain of body weakness. Every time they are active, the weakness decreases if the patient rests. The patient was stated to be suffering from anemia and a left kidney tumor. There was bilateral antebrachial pitting edema. There was bilateral pretibial edema. Cytological examination revealed papillary renal cell carcinoma type 1. Conclusion: Papillary cell carcinoma type 1 is a kidney tumor that has a good prognosis, especially if found at an early stage. The classic symptoms of type 1 pRCC are anemia, hematuria and kidney swelling